-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Antiviral-agent-15
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/antiviral-agent-15.gif)
| Category | SARS-CoV |
| Description | Antiviral agent 15 (Compound 15f) is a Clofazimine derivative with antiviral effects. Antiviral agent 15 inhibits both rabies virus and pseudo-typed SARS-CoV-2 with EC50 values of 1.45 μM and 14.6 μM, respectively. |
Product Information
| Synonyms | Antiviral agent 15|HY-144623|CS-0433077 |
| Molecular Weight | 453.51 |
| Molecular Formula | C27H24FN5O |
| Canonical SMILES | CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=NC=C(C=C4)OC)C=C1NC5=CC(=CC=C5)F |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 865 |
| Exact Mass | 453.19648857 |
| In Vitro | Antiviral agent 15 (Compound 15f) affects the rabies and SARS-CoV-2 proliferation by targeting G or S protein to block the viral membrane fusion, as well as binding to L protein or nsp13 to inhibit viral biosynthesis, respectively, and thus synergistically exerted antiviral effect. |
| In Vivo | In Kunming mice, Antiviral agent 15 is given orally in a single-dosing experiment at 0 mg/kg, 200 mg/kg, 400 mg/kg, 600 mg/kg and 800 mg/kg, respectively. The mice are closely monitored for 7 days, and all the surviving mice had glossy hair, fleshy body and good appetiteantiviral agents with dual-target mechanism. |
| Target | SARS-CoV |
| XLogP3-AA | 5.2 |
